secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2022-02-02T23:59:59+00:00
Accession:  0001651308-22-000013
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

China accepts BRUKINSA sNDA for CLL/SLL with breakthrough therapy; board adds two directors
--------------------------------------------------------------------------------

- China NMPA accepted sNDA for BRUKINSA (zanubrutinib) in CLL/SLL, supported by Phase 3 SEQUOIA trial (HR=0.42 for PFS vs B+R).
- First breakthrough therapy designation for BRUKINSA in China; filing seeks expansion from relapsed/refractory to frontline use.
- Director Jing-Shyh (Sam) Su resigned Jan 31, 2022; no disagreement disclosed.
- Board expanded to 12; appointed Margaret Dugan, M.D. and Alessandro Riva, M.D. effective Feb 1, 2022.
- New directors receive standard cash compensation ($60K/yr) and share options valued at $400K each, pro-rated first year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130822000013/0001651308-22-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130822000013/bgne-20220128.htm
  HTML page:      https://secwatch.observer/filing/0001651308-22-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer